Sykes Lab focused on the study of healthy and malignant hematopoiesis.
Missouri, USA
Joined May 2019
- Tweets164
- Following203
- Followers515
- Likes269
Stephen Sykes retweeted
Take your research beyond the lab! Join the Junior Faculty Committee on 21 October to learn how research commercialisation can transform scientific discoveries into real-world products and services. iseh.org/Webinars-Events/Web…
Stephen Sykes retweeted
Congratulations to Sweta and the rest of the team on our new publication in @BCD_AACR exploring the dependence and therapeutic targeting of NAMPT in high-risk MDS stem cells. Thanks to @BloodCancerUtd and Evans Foundation for support! aacrjournals.org/bloodcancer…
Stephen Sykes retweeted
Very grateful for the support from @DamonRunyon & @ASH_hematology, and to @SitemanCancer for highlighting our AML research. So thankful to our amazing team, mentors & collaborators! 🩸🔬
siteman.washu.edu/rising-was…
Stephen Sykes retweeted
✨ Thrilled to share our new publication in Nature.
We define an “inflammatory memory” HSC state (HSC‑iM), linking lifelong inflammatory exposure to aging and disease.
📄 Article: nature.com/articles/s41586-0…
Grateful to an incredible team and global collaborators 💚💙
Stephen Sykes retweeted
Our newest preprint is now online! We lift up the hood on TET2 mutant clonal hematopoiesis and show that oxidative metabolism is a critical feature of TET2 deficient HSPC - with compensatory redox control as a potential vulnerability.
biorxiv.org/content/10.64898…
Stephen Sykes retweeted
Happy to see our study finally published in @BCD_AACR! 🎉 Thanks again to the lead authors @mp_hartmann, Maximilian Schönung and all collaborators who helped to put together the bits and pieces of this exciting story! 🙏👏
Just published in @BCD_AACR:
Molecular Plasticity Results in #Oncofetal #Reprogramming and Therapeutic Vulnerabilities in JMML, by @mp_hartmann @dlipka1
Check out new insights into cell-of-origin, and repurposing anti-CD52.
doi.org/10.1158/2643-3230.BC…
Stephen Sykes retweeted
Dr. Ross Levine (@rosslevinemd), Senior Vice President of Translational Research at MSK, has been named MSK's new Chief Scientific Officer (CSO).
Dr. Levine will be responsible for setting and leading strategy for basic and translational research, including programs, centers, and technology cores.
Congratulations, Dr. Levine!
bit.ly/4nQAeNj
Stephen Sykes retweeted
How it started (undergrad who thinks grant writing is fun🤓) vs how it’s going (A PAPER IN BLOOD🩸!) excited to share the FULL ATF6 story with the world! Thank you to my amazing co-authors and mentor @TheElfLab for helping my six year long dream come true! ashpublications.org/blood/ar…
Stephen Sykes retweeted
Read our latest #research on #extramedullaryAML published with @SpringerNature in @BloodCancerJnl Thanks to the @LeukemiaRF for funding this work!
⬇️⬇️⬇️
rdcu.be/eADE4
Stephen Sykes retweeted
I am deeply honored and immensly grateful to the scientific community at ISEH for receiving this award! And a big shoutout and thank you to all the brilliant and hard-working former and current members of my lab who made the progress possible that led to this award! 😊 🙏
ISEH is thrilled to announce the recipients of the 2025 Society Awards, which will be presented at the ISEH 54th Annual Scientific Meeting. Read more about each award recipient on simplyblood.org/
Stephen Sykes retweeted
Unsolicited advice to new PIs and my opinion only not fact:
As a new Assistant Professor, you have a 1-1.5 year window where you can get an R01 without a corresponding author paper IF you have a high impact 1st author paper from your postdoc.
After that, it seems no amount of data in your R01 application matters anymore. The study section is looking for a peer reviewed publication. The important thing here is that it does not need to be high impact. They are looking for execution. Can you deliver the final product?
“I don’t have time. Is there an alternative?” Put paper on preprint server and get it sent out at a respectable journal and note that in your R01 application. The study section may let this slide.
Again, my OPINION based on my own experience. Good luck to all new PIs I know it’s a tough time.
Stephen Sykes retweeted
Thrilled and honored to have received an @AIRC_it StartUp grant to support my leukemia research here at @unipr !
Biomarcatori tumorali e lotta alle #leucemie acute
Due nuovi progetti di ricerca di #unipr finanziati da @AIRC_it per la Ricerca sul Cancro
▶️My First AIRC Grant ad Alessandro Bertucci e Start-Up Grant a Orsola di Martino
#RicercaUnipr #StudiareAParma
unipr.it/notizie/biomarcator…
Stephen Sykes retweeted
Our preprint using EGFL7 to expand HSCs is FINALLY out 🙌🏻 🎉 🩸 biorxiv.org/content/10.1101/…
Stephen Sykes retweeted
Delighted to see our CLN1 & CLN2 Enteric Nervous System gene therapy paper published in @ScienceTM today! Big team effort with many great colleagues @HeuckerothLab @WashUMedPeds & directly inspired by Batten families @BDSRA @NIH_NINDS @noahs_hope1 science.org/doi/10.1126/scit…
Stephen Sykes retweeted
Excited to share our latest work published today in @SciImmunology and featured on the cover! This study demonstrates that thrombospondin-1 (Thbs1) is a driver of hematopoietic aging and that targeting Thbs1 suppresses inflammaging and restores systemic and HSC healthspan.
Science #Immunology's January issue is out!
This month's cover depicts how deleting #thrombospondin1 can reverse aging-associated defects known as #inflammaging in hematopoietic stem cells in mice.
Read this research and more: scim.ag/3BI2A9Z
